Ausgabe 2/2014
Inhalt (31 Artikel)
Cost-effectiveness analysis of extended adjuvant endocrine therapy in the treatment of post-menopausal women with hormone receptor positive breast cancer
Aysegul Erman, Arlene Nugent, Eitan Amir, Peter C. Coyte
Androgenic pathways in the progression of triple-negative breast carcinoma: a comparison between aggressive and non-aggressive subtypes
Keely M. McNamara, Tomomi Yoda, Alif Meem Nurani, Yukiko Shibahara, Yasuhiro Miki, Lin Wang, Yasuhiro Nakamura, Koyu Suzuki, Yang Yang, Eriko Abe, Hisashi Hirakawa, Takashi Suzuki, Noriko Nemoto, Minoru Miyashita, Kentaro Tamaki, Takanori Ishida, Kristy A. Brown, Noriaki Ohuchi, Hironobu Sasano
Prognostic relevance of glycosylation-associated genes in breast cancer
Karin Milde-Langosch, Thomas Karn, Marcus Schmidt, Christine zu Eulenburg, Leticia Oliveira-Ferrer, Ralph M. Wirtz, Udo Schumacher, Isabell Witzel, Dina Schütze, Volkmar Müller
RANK expression as a prognostic and predictive marker in breast cancer
Berit Maria Pfitzner, Daniel Branstetter, Sibylle Loibl, Carsten Denkert, Bianca Lederer, Wolfgang Daniel Schmitt, Frank Dombrowski, Martin Werner, Thomas Rüdiger, William C. Dougall, Gunter von Minckwitz
Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer
Dena A. Jerjees, M. Alabdullah, Andrew R. Green, Alaa Alshareeda, R. D. Macmillan, Ian O. Ellis, Emad A. Rakha
Surgical excision of radial scars diagnosed by core biopsy may help predict future risk of breast cancer
Cynthia L. Miller, Jane A. West, Anna C. Bettini, Frederick C. Koerner, Thomas M. Gudewicz, Phoebe E. Freer, Suzanne B. Coopey, Michele A. Gadd, Kevin S. Hughes, Barbara L. Smith, Elizabeth Rafferty, Michelle C. Specht
Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and reverse phase protein array study
Mohammed A. Aleskandarany, Ola H. Negm, Andrew R. Green, Mohamed A. H. Ahmed, Christopher C. Nolan, Patrick J. Tighe, Ian O. Ellis, Emad A. Rakha
The endoplasmic reticulum stress markers GRP78 and CHOP predict disease-free survival and responsiveness to chemotherapy in breast cancer
Yi-Zi Zheng, Zhi-Gang Cao, Xin Hu, Zhi-Ming Shao
Regulation of apoptosis by long non-coding RNA GAS5 in breast cancer cells: implications for chemotherapy
Mark R. Pickard, Gwyn T. Williams
Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor®) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study
Gilbert Donders, Patrick Neven, Maximilian Moegele, Anneleen Lintermans, Gert Bellen, Valdas Prasauskas, Philipp Grob, Olaf Ortmann, Stefan Buchholz
A randomized, placebo-controlled trial of melatonin on breast cancer survivors: impact on sleep, mood, and hot flashes
Wendy Y. Chen, Anita Giobbie-Hurder, Kathryn Gantman, Jennifer Savoie, Rochelle Scheib, Leroy M. Parker, Eva S. Schernhammer
Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling
Vandana G. Abramson, M. Cooper Lloyd, Tarah Ballinger, Melinda E. Sanders, Liping Du, Darson Lai, Zengliu Su, Ingrid Mayer, Mia Levy, Delecia R. LaFrance, Cindy L. Vnencak-Jones, Yu Shyr, Kimberly B. Dahlman, William Pao, Carlos L. Arteaga
Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression
Masashi Ando, Hideko Yamauchi, Kenjiro Aogi, Satoru Shimizu, Hiroji Iwata, Norikazu Masuda, Naohito Yamamoto, Kenichi Inoue, Shinji Ohono, Katsumasa Kuroi, Tetsutaro Hamano, Tamie Sukigara, Yasuhiro Fujiwara
A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease
Robert Coleman, Anne-Kirsti Aksnes, Bjørn Naume, Camilo Garcia, Guy Jerusalem, Martine Piccart, Nancy Vobecky, Marcus Thuresson, Patrick Flamen
Tamoxifen-associated hot flash severity is inversely correlated with endoxifen concentration and CYP3A4*22
Simon D. Baxter, Wendy A. Teft, Yun-Hee Choi, Eric Winquist, Richard B. Kim
Re-attendance at biennial screening mammography following a repeated false positive recall
Elisabeth G. Klompenhouwer, Lucien E. M. Duijm, Adri C. Voogd, Gerard J. den Heeten, Luc J. Strobbe, Marieke W. Louwman, Jan Willem Coebergh, Dick Venderink, Mireille J. M. Broeders
Fatal breast cancer risk in relation to use of unopposed estrogen and combined hormone therapy
Gaia Pocobelli, Polly A. Newcomb, Christopher I. Li, Linda S. Cook, William E. Barlow, Noel S. Weiss
Erratum to: Fatal breast cancer risk in relation to use of unopposed estrogen and combined hormone therapy
Gaia Pocobelli, Polly A. Newcomb, Christopher I. Li, Linda S. Cook, William E. Barlow, Noel S. Weiss
Clinical and molecular characterization of the BRCA2 p.Asn3124Ile variant reveals substantial evidence for pathogenic significance
Harald Martin Surowy, Christian Sutter, Max Mittnacht, Ruediger Klaes, Dieter Schaefer, Christina Evers, Anna Lena Burgemeister, Caroline Goehringer, Nicola Dikow, Joerg Heil, Michael Golatta, Sarah Schott, Andreas Schneeweiss, Peter Bugert, Christof Sohn, Claus Rainer Bartram, Barbara Burwinkel
Adolescent dietary fiber, vegetable fat, vegetable protein, and nut intakes and breast cancer risk
Ying Liu, Graham A. Colditz, Michelle Cotterchio, Beatrice A. Boucher, Nancy Kreiger
Birth size in the most recent pregnancy and maternal mortality in premenopausal breast cancer by tumor characteristics
Mohammadhossein Hajiebrahimi, Sven Cnattingius, Mats Lambe, Chung-Cheng Hsieh, Johan Ahlgren, Jan Adolfsson, Shahram Bahmanyar
Use of menopausal hormone therapy and risk of ductal and lobular breast cancer among women 55–74 years of age
Christopher I. Li, Janet R. Daling, Kara L. Haugen, Mei Tzu Chen Tang, Peggy L. Porter, Kathleen E. Malone
Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy
Rachel A. Freedman, Ines Vaz-Luis, William T. Barry, Huichuan Lii, Nancy U. Lin, Eric P. Winer, Nancy L. Keating
Prognostic factors for survival in metastatic breast cancer by hormone receptor status
A. B. G. Kwast, A. C. Voogd, M. B. E. Menke-Pluijmers, S. C. Linn, G. S. Sonke, L. A. Kiemeney, S. Siesling
Folate intake and the risk of breast cancer: a systematic review and meta-analysis
Martin Tio, Juliana Andrici, Guy D. Eslick
Contributors to nonadherence and nonpersistence with endocrine therapy in breast cancer survivors recruited from an online research registry
Annette L. Stanton, Keith J. Petrie, Ann H. Partridge
Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort
Agnès Fournier, Sylvie Mesrine, Laure Dossus, Marie-Christine Boutron-Ruault, Françoise Clavel-Chapelon, Nathalie Chabbert-Buffet
Associations between anthropometric characteristics, physical activity, and breast cancer risk in a Canadian cohort
Chelsea Catsburg, Victoria A. Kirsh, Colin L. Soskolne, Nancy Kreiger, Erin Bruce, Thi Ho, Scott T. Leatherdale, Thomas E. Rohan
Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations
Anna P. Sokolenko, Natalia Bogdanova, Wojciech Kluzniak, Elena V. Preobrazhenskaya, Ekatherina S. Kuligina, Aglaya G. Iyevleva, Svetlana N. Aleksakhina, Natalia V. Mitiushkina, Tatiana V. Gorodnova, Alexandr A. Bessonov, Alexandr V. Togo, Jan Lubiński, Cezary Cybulski, Anna Jakubowska, Thilo Dörk, Evgeny N. Imyanitov
Letter in response: breast cancer screening of women aged 70–74 years
Robert Burton
Rebuttal to: Letter to the Editor by Robert Burton, in response to doi:10.1007/s10549-013-2794-5
Carolyn Nickson, Kate E Mason, Anne M. Kavanagh